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Abstract
Background: Secondary dystroglycanopathies are a subset of muscular dystrophy caused by abnormal glycosylation
of α-dystroglycan (αDG). Loss of αDG functional glycosylation prevents it from binding to laminin and other
extracellular matrix receptors, causing muscular dystrophy. Mutations in a number of genes, including FKTN (fukutin),
disrupt αDG glycosylation.
Methods: We analyzed conditional Fktn knockout (Fktn KO) muscle for levels of mTOR signaling pathway proteins by
Western blot. Two cohorts of Myf5-cre/Fktn KO mice were treated with the mammalian target of rapamycin (mTOR)
inhibitor rapamycin (RAPA) for 4 weeks and evaluated for changes in functional and histopathological features.
Results: Muscle from 17- to 25-week-old fukutin-deficient mice has activated mTOR signaling. However, in
tamoxifen-inducible Fktn KO mice, factors related to Akt/mTOR signaling were unchanged before the onset of
dystrophic pathology, suggesting that Akt/mTOR signaling pathway abnormalities occur after the onset of disease
pathology and are not causative in early dystroglycanopathy development. To determine any pharmacological
benefit of targeting mTOR signaling, we administered RAPA daily for 4 weeks to Myf5/Fktn KO mice to inhibit
mTORC1. RAPA treatment reduced fibrosis, inflammation, activity-induced damage, and central nucleation, and
increased muscle fiber size in Myf5/Fktn KO mice compared to controls. RAPA-treated KO mice also produced
significantly higher torque at the conclusion of dosing.
Conclusions: These findings validate a misregulation of mTOR signaling in dystrophic dystroglycanopathy
skeletal muscle and suggest that such signaling molecules may be relevant targets to delay and/or reduce
disease burden in dystrophic patients.
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Background
The dystrophin-glycoprotein complex (DGC) provides a
critical link between the extracellular matrix and the intra-
cellular cytoskeleton to enhance cell membrane stability
[1–3]. α-Dystroglycan (αDG) is an extracellular protein
within the DGC that acts as a receptor for laminin and
other matrix proteins, but it requires the presence of a rare
O-mannose glycan structure for this function [1, 4–8].
Disruption of αDG O-mannose glycosylation impairs its
laminin-binding activity causing a group of diseases known
collectively as secondary dystroglycanopathies, which are
characterized by progressive muscle pathology along with
variable involvement of the brain and eyes [9]. To date,
mutations in at least 15 genes, including FKTN, encoding
fukutin, have been identified as causative for secondary
dystroglycanopathies [10–13]. Recently, fukutin has
been directly implicated in the modification of the core
M3 O-mannose structure on αDG as a ribitol-5-
phosphate transferase that acts upstream of functional
modification by like-acetylglucosaminyl transferase
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(LARGE) [14]. Despite these advances, current thera-
peutic strategies for dystroglycanopathies are limited,
and they remain without treatment or cure.
Disease pathology in DGC-related muscular dystrophies
has been attributed to increased susceptibility of the
sarcolemma to contraction-induced damage following dis-
ruption of αDG-laminin binding, leading to cycles of
muscle degeneration and regeneration [2]. Dystrophic
muscles lose regenerative capacity over time and muscle
fibers are gradually replaced with fibrotic or fatty tissues
[15–17]. However, recent evidence suggests that loss of
dystroglycan functional glycosylation induces develop-
mental and regeneration-specific defects that may also
contribute to disease severity [18–22].
To date, signaling studies in models of dystroglycanopa-
thy have been limited; however, disruption of αDG-
laminin interactions might result in downstream signaling
consequences. Antibody-mediated laminin detachment
has been shown to dysregulate the serine/threonine kinase
Akt (protein kinase B), leading to increased apoptosis in
cultured myotubes [23]. While best known for its role in
cell survival, Akt is also critical for a number of physio-
logical processes in the muscle and has been implicated in
the progression of dystrophy in dystrophin-deficient mice
[24–26]. Akt is activated through phosphorylation at
threonine 308 (T308) by phosphoinositide-dependent
kinase 1 (PDK1) and at serine 473 by phosphoinositide-
dependent kinase 2 (PDK2). More recently, the elusive
PDK2 has been identified as a rapamycin-insensitive com-
plex of mammalian target of rapamycin (mTOR), known
as mTOR complex 2 (mTORC2) [27]. Activation of Akt
leads to the downstream activation of mTOR complex 1
(mTORC1), which stimulates muscle growth and hyper-
trophy through increased protein synthesis [28, 29]. Inter-
estingly, mTOR inhibition decreased muscle necrosis and
effector T cell infiltration in the mdx mouse, a mild model
of Duchenne and Becker muscular dystrophies (DMD/
BMD) [30]. Importantly, the muscles from human dystro-
glycanopathy patients and animal models of disease dem-
onstrate a marked variability in fiber size within a given
tissue, often displaying abnormally high populations of
both hypertrophic and atrophic cells [18, 31]. These find-
ings suggest that abnormal regulation of cell growth path-
ways may be a factor contributing to disease pathology.
Altogether, manipulation of the molecular mechanisms
controlling cell growth and viability might offer an avenue
towards the amelioration of dystrophic pathology. Indeed,
previous studies have indicated the therapeutic benefit of
engaging cell survival signaling [32] or modulating cellular
processes involved in cell size, including protein synthesis
(through mTOR) and autophagy in other types of muscu-
lar dystrophy [33, 34].
In the present study, we show that 17–25-week-old
(hereafter, “aged”) Fktn-deficient dystroglycanopathy
mice with later-stage muscular dystrophy have increased
activation of mTOR. However, induction of Fktn loss
post-development (in 6-week-old mice) failed to change
activation status of signaling proteins involved in the
mTOR pathway prior to the onset of muscle pathology,
indicating that mTOR activation may be a byproduct of
the disease state. To better understand whether this
change corresponds to pathogenic or compensatory pro-
cesses in dystroglycanopathy muscle, we investigated the
ability of the mTOR inhibitor rapamycin (RAPA) to alter
dystrophic pathology. Daily oral dosing of RAPA from 8
to 12 weeks of age reduced histopathology, including
proportions of centrally nucleated (CN) muscle fibers,
and protected against increased serum creatine kinase
(CK) levels following a damaging downhill treadmill run
in Myf5/Fktn knockout (KO) mice. Ankle dorsiflexors
[tibialis anterior (TA), extensor digitorum longus (EDL),
and extensor hallucis longus muscles] of RAPA-treated
KO mice also produced significantly higher torque post-
vs. pre-study, in contrast to untreated KO mice.
Immunofluorescent analysis of iliopsoas after comple-
tion of the 4-week RAPA study demonstrated mTOR
activation (determined by pS6 localization) in both
muscle and non-muscle compartments of dystrophic
tissue. However, pS6 levels correlated closely with levels
of fibrosis in VEH- but not RAPA-treated KO mice.
Biochemical analysis revealed increased levels of proteins
involved in autophagosome formation in untreated KO
mice which were partially reduced following 4 weeks of
RAPA treatment. Overall, our data suggest that manipu-
lations in the mTOR pathway may have potential thera-
peutic benefit. Future studies will be important to define
the best pharmacological agents and molecular targets




The following primary antibodies used in this study
were purchased from commercial suppliers: rabbit anti-
Akt, p-Akt (S473 and T308), S6, p-S6 (S235/236), p-
mTOR (S2448), mTOR, Beclin-1, LC3B, glyceraldehyde
3-phosphate dehydrogenase (GAPDH), and mouse anti-
S6 from Cell Signaling (cat# 4691, 4060, 2965, 2217,
4858 or 2211, 5536, 2983, 3738, 2775, 5174, 2317);
rabbit anti-Vps15 (A302-571A) from Bethyl Laborator-
ies; rat anti-perlecan from Millipore (MAB1948P); rat
anti-CD11b from Fisher (BD Biosciences, BDB550282);
dystrophin (MANDYS16) and embryonic myosin heavy
chain (eMHC, F1.652) from the Developmental Studies
Hybridoma Bank (DSHB); and rabbit anti-collagen VI
(ColVI, 70R-CR009x) from Fitzgerald Industries. Anti-
bodies detecting functionally glycosylated αDG (IIH6)
and β-dystroglycan protein (βDG, 7D11) have been
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described previously [1, 35] and were a gift from Dr. Kevin
Campbell (U. Iowa) or purchased from DSHB. αDG-core
antibodies (45-3, 5-2) were reported recently [36]. Second-
ary antibodies conjugated to horseradish peroxidase or
Alexa Fluor® 488 or 546 were purchased from Millipore,
Jackson ImmunoResearch, or Life Technologies.
Mice
All mouse husbandry and experimental procedures were
approved by the University of Georgia Institutional Animal
Care and Usage Committee under Animal Use Protocols
A2010 08-153 and A2013 07-016 (Beedle). Mice were
maintained on a 12:12 h light:dark cycle. Earclips were
taken for identification and genotyping. Myf5/Fktn con-
ditional KO and Tam/Fktn inducible KO mice have
been described previously [18, 19]. Female mice homo-
zygous for loxP-flanked (floxed) Fktn exon 2 (FktnL/L)
were crossed to male mice heterozygous for the floxed
Fktn allele and hemizygous for Myf5-driven Cre-
recombinase (Myf5Cre/+, FktnL/+) to generate developmen-
tal skeletal muscle knockout of Fktn (Myf5Cre/+, FktnL/L,
called Myf5/Fktn KO). Whole animal tamoxifen-inducible
KO mice (driven by the CAGGCre-ER promoter; Jackson
Laboratories, strain #004682) were generated by crossing
TgCre-esr1/+, Fktn+/− and floxed Fktn (FktnL/L) mice to give
TgCre-esr1/+, FktnL/− progeny (Tam iKO). Due to the
incorporation of the null allele, tamoxifen-induced Cre-
recombination is required at only one allele to guarantee
Fktn loss. Both female and male knockout and littermate
mice were used for all studies with no preference or spe-
cial consideration for sex. All study mice, except for the
daily rapamycin dosing study with treadmill endpoint,
were fasted for 12 h (over the light cycle) prior to tissue
collection. For mice in the daily rapamycin dosing study
with muscle torque endpoint, the fast was started in the
evening following muscle torque measurements for eutha-
nization and tissue collection the following morning.
Tamoxifen dosing
Tamoxifen (Sigma-Aldrich or Cayman Chemical) was dis-
solved in 200 proof ethanol and diluted in sunflower seed
oil (Sigma-Aldrich) heated to 70 °C. Mice were given two
10 mg doses of tamoxifen by gavage 2 days apart at
6 weeks of age and one additional dose the week of tissue
collection. A total of 18 mice were dosed for the study:
nine Tam iKO and nine Tam littermate control (LC; Tg+/+,
FktnL/−; Tg+/+, FktnL/+; or TgCre-esr1/+, FktnL/+).
mTOR pathway pharmacological dosing
Ten milligrams per milliliter stock solutions of rapamycin
(RAPA, Calbiochem or VWR Scientific) were made in
DMSO (Sigma-Aldrich) and stored at −20 °C. A working
solution of 0.5 mg/ml was made by 1:20 dilution in 0.9 %
saline. Five percent DMSO in 0.9 % saline was dosed to
vehicle control mice (VEH). Insulin (Sigma-Aldrich) was
stored as a 7.5 mg/ml stock in 1 % acetic acid and was
diluted 1:10 in 0.9 % saline to provide a working solution
of 0.75 mg/ml (0.1 % acetic acid in 0.9 % saline was used
as the vehicle control). For single dose studies, mice were
fasted for a total of 12 h and given vehicle or insulin by
intraperitoneal injection at a dose of 0.1 U/g 30 min prior
to sacrifice or given vehicle or RAPA (2 mg/kg) by gavage
6 h prior to dissection. A total of five Myf5/Fktn KO mice
were dosed with vehicle, five with rapamycin, and five with
insulin. A total of four littermates were dosed with vehicle,
five with rapamycin, and six with insulin.
Daily study mice were administered vehicle (VEH LC
or KO) or 2 mg/kg RAPA (RAPA LC or KO) by oral
gavage once a day for 4 weeks. In the first daily dosing
study (with muscle torque endpoint), five mice were
used in each group. In the second daily study (with
treadmill endpoint), eight and seven Myf5/Fktn KO mice
were dosed with RAPA and vehicle, respectively, and six
RAPA-treated and six vehicle-treated littermate controls
(LC; Myf5Cre/+, FktnL/+; Myf5+/+, FktnL/L; or Myf5+/+,
FktnL/+) were used. One RAPA KO met statistical criter-
ion for exclusion and was therefore not included in the
final dataset (see statistics).
Physiological measurements
Mice in the daily rapamycin treatment study were ana-
lyzed for serum creatine kinase levels before and after a
downhill exhaustion treadmill run. Mice were equilibrated
to a four-lane mouse treadmill (Accuscan) at a −10° angle
for two 30-min session (25 min at 0 m/min, 5 min at 3 m/
min) on days 1 and 2 after the last RAPA or VEH dose.
Blood was collected from the ventral tail artery of study
mice after the second equilibration session (“pre-exhaus-
tion bleed”). On the third day post-dosing, mice were run
using the downhill exhaustion protocol (warm-up 5 min
at 3 m/min; downhill exhaustion run 5 min at 10 m/min,
5 min at 15 m/min, 5 min at 20 m/min, and up to 15 min
at 25 m/min) [18]. When mice remained on the shock
pad for ten consecutive seconds, exhaustion time was re-
corded and mice were removed from the treadmill. Tread-
mill run distances for Myf5/Fktn KO mice are reported as
a normalized comparison to distances of cage- and/or
age-matched LC mice running a simultaneous exhaustion
protocol. Two hours after the run end, a post-treadmill
blood sample was collected and mice were sacrificed for
tissue collection. For creatine kinase measurements,
serum was diluted 1:10 in ultrapure water and added to
creatine kinase reagent (StanBio) according to the manu-
facturer’s protocol. The resulting mixture was assayed for
CK activity using a Synergy 2 microplate reader (BioTek
Instruments).
Torque was measured from the ankle dorsiflexors of mice
as previously described [37, 38]. Mice were anesthetized
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with 1.5 % isoflurane-mixed oxygen, hair was removed
from the left lower hind limb, and the foot was attached to
a servomotor for torque measurement (Aurora Scientific,
Aurora Canada). Muscle contraction was stimulated using
Pt-Ir needle electrodes inserted percutaneously adjacent to
the peroneal nerve using 1 to 2 mA (stimulator model
701C, Aurora Scientific). Isometric torque was measured in
response to 20, 40, 60, 80, 100, 125, 150, and 200 Hz of
stimulation frequency. Each mouse in the RAPA daily study
with muscle torque testing underwent two separate muscle
torque exams, one prior to the onset of RAPA or VEH dos-
ing (the “pre” test) and one on the day following the 28th
RAPA or VEH dose (the “post” test). Torque measurements
were normalized to body mass (in kilograms) for each
mouse to account for size differences between animals.
Kidney and liver toxicity measurements
Blood urea nitrogen (BUN) and serum alanine transamin-
ase (ALT) were assayed using kits purchased from Arbor
Assays and Cayman Chemicals, respectively. For BUN,
serum was diluted 1:20 in ultrapure H2O and analyzed by
colorimetry according to the manufacturer’s protocol on a
Spectramax microplate reader using Softmax Pro 5.3 soft-
ware (Molecular devices). ALT was detected in serum
diluted 1:10 in ultrapure H2O via consumption of NADH
in a coupled reaction. Absorbance measurements were
taken at 340 nm (Synergy 2 microplate reader) every
minute for 5 min and the average rate of change across a
linear range was used to quantitate ALT.
Succinate dehydrogenase measurement
TA muscles were homogenized on ice with a glass-on-
glass dounce homogenizer in 2 ml of 33 mM PO4
3− buffer.
Samples were aliquoted and taken through 3 cycles of
freezing and thawing before use. A method for spectro-
photometric determination of succinate dehydrogenase
[39] was adapted for the microplate. Triplicate 4 or 8 μl
volumes of tissue homogenate were incubated with 10 μl
of 0.5 M sodium succinate for 2 min at 30 °C. Ten micro-
liters of sodium cyanide was mixed into samples followed
by 300 μl cytochrome C working reagent (0.1 M cyto-
chrome C from equine heart in 0.17 M PO4
3− buffer,
0.004 M AlCl3/CaCl2, and H2O mixed 2.5:1:7.5) immedi-
ately prior to reading (Spectramax microplate reader).
Reduction of cytochrome C was assessed by kinetic
absorbance measurements at 550 nm. Data are presented
as micromole cytochrome c reduced per minute per mg
tissue mass.
Histology and microscopy
Seven-micron tissue cryosections were stained by
hematoxylin and eosin (H&E) according to standard pro-
tocols. Sections were processed for secondary immuno-
fluorescence (IF) as described previously [18, 19, 40].
H&E- or immunofluorescent-stained skeletal muscle sec-
tions were imaged using an X71 inverted epifluorescent
microscope with a Peltier element-cooled 12.8MP DP72
CCD camera and CellSens software (Olympus).
For analysis of eMHC, αDG glycosylation (IIH6) and
central nucleation, tiled ×20 images were taken across
each entire muscle section and aligned to compile entire
section maps in Photoshop (Adobe), then positive and
negative fibers were counted manually using ImagePro
Express (MediaCybernetics). Data are reported as per-
centages obtained by dividing the number of positive
fibers by the total number of muscle fibers in an entire
muscle section. Tissue maps from this analysis were also
used for measurement of muscle fiber minimum diam-
eter. Perimeters of individual muscle fibers were traced
in a semi-automated fashion using a combination of
manual segmentation (dark objects) and manual polygon
selection in ImagePro Premier v9.1 (Media Cybernetics),
which calculated minimum diameter according to a ref-
erence distance (scale bar). Area values were sorted
according to size, grouped into bins of 2.5 μm (estimated
from the formula h ¼ 3:5σn1=3 , where h is the optimized bin
size, σ is the standard deviation, and n is the number of
observations), up to a maximum of 30 μm and plotted
as a histogram. Analyses were performed blinded to
experimental group and study design.
Sections incubated with anti-collagen VI, anti-CD11b,
or anti-pS6 were imaged and mapped as above. Whole
section maps were analyzed for fluorescent area using
Fiji (ImageJ, [41]) software. Briefly, a region of interest
was drawn to encircle the entire muscle section. The
number of pixels/section was quantified and a color
threshold was set. Pixels at brightness above the color
threshold were considered positive for collagen VI,
CD11b, or pS6; these pixels were selected and counted.
Data are expressed proportion of area, which is the
number of positive pixels/total number of pixels in the
section for each map.
Western blotting
Pooled hind limb muscles (soleus, gastrocnemius, tibialis
anterior [TA], hamstring, quadriceps, and gluteus) or
isolated quadriceps from individual mice were homoge-
nized and solubilized in buffer containing 50 mM Tris
(pH 7.4), 150 mM NaCl, 1 % Triton-X, and a homemade
cocktail of phosphatase and protease inhibitors: pepsta-
tin A, 0.6 μg/ml; aprotinin, 0.5 μg/ml; leupeptin, 0.5 μg/
ml; phenylmethanesufonylfluoride, 0.1 mM; benzami-
dine, 0.75 mM; calpain I inhibitor, 2 μM; calpeptin,
2 μM; NaF, 50 mM; NaPPi, 10 mM; and β-
glycerophosphate, 10 mM. Initial studies included
NaVO4 for inhibition of tyrosine and alkaline phospha-
tases. However, there was marked sample precipitation
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over time, so NaVO4 was excluded from all samples re-
ported here. Insoluble material was pelleted at ×142,000g
for removal, and the resulting supernatant was filtered
through cheesecloth. Protein concentrations were deter-
mined using a modified DC protein assay (Bio-Rad) with a
SpectraMax microplate reader (Molecular Devices).
Solubilized skeletal muscle protein samples (500 μg)
were loaded onto 3–15 % gradient gels for SDS-PAGE.
Protein was transferred to PVDF (Millipore), blocked with
1 % milk in Tris-buffered saline with 0.1 % Tween-20
(TBS-T), and probed with primary antibody overnight, as
described previously [18, 40]. Secondary antibodies conju-
gated to horseradish peroxidase were used, and blots were
imaged with West Pico or West Dura chemiluminescent
reagent (Pierce) and the Fluorchem HD2 digital imager
(Protein Simple). All study mice (n = 4–8 per group) from
each group were tested by Western blot with a minimum
of two technical replicates. One sample (VEH LC) in the
daily RAPA dosing study was unfit for analysis by Western
blot and was excluded from those data sets.
Cytokine/chemokine multiplex assay
Transforming growth factor-β (TGF-β, TGFBMAG-
64 K-01) or mouse cytokine/chemokine (MCYTOMAG-
70k: interleukin-1β, monocyte chemotactic protein-1,
and tumor necrosis factor-α) magnetic bead kits were
purchased from Millipore for analysis via the Luminex
xMAP platform. Solubilized protein (50 μg) or diluted
serum samples (1:30, TGF-β; 1:4 cytokine/chemokine
multiplex) were loaded onto a pre-wet 96-well plate and
incubated with antibody-conjugated magnetic beads
overnight at 4 °C. Beads were pelleted using a handheld
magnet, samples were decanted, and pelleted beads were
resuspended in the presence of biotinylated detection
antibodies. Finally, the beads were treated with
streptavidin-conjugated phycoerythrin and imaged with
the MAGPIX (Luminex Corp.) using xPONENT 4.2
software. Median fluorescent intensity (MFI) for each
sample was normalized as fold increase over background
MFI.
Graphing, data analysis, and statistics
Band densitometry for Western blot was measured using
AlphaView 3.0 software (Protein Simple). Band inten-
sities of a given blot were set as a proportion of the max-
imum intensity (equal to 1), and these values for the
protein of interest were normalized to the corresponding
value of the total protein content for phopho-epitopes of
signaling proteins or to loading control (GAPDH) for all
others.
Data are plotted as scatter plots (each individual data
point represents one study mouse) with the group mean
and standard error of the mean using Prism 5 (GraphPad).
As a number of plots contained possible outlier samples, a
Dixon’s q-test [42, 43] was applied to every data set with a
critical value of α = 0.05 to identify true outliers. A num-
ber of datasets contained an outlier in one of the study
groups. For the most part, the individual outlier mouse
was not consistently an outlier across datasets; therefore,
no action was taken in these cases. However, one mouse
in the daily dosing study was a clear outlier in the majority
of its datasets. Therefore, this mouse was excluded from
reported data. Differences between study groups were
determined by two-tailed Student’s t test or two-way ana-
lysis of variance (ANOVA) with Bonferroni’s post-test in
Prism 5. The interaction (e.g., Drug*Genotype) p value
from two-way ANOVA analysis is reported on all figures,
and individual main effects (e.g., drug, genotype) are
reported only in the absence of a significant interaction
between variables. Statistical significance between groups
is denoted by *p < 0.05; **p < 0.01; ***p < 0.001. A signifi-
cant difference between one group and two or more other
groups is represented on plots by a line originating from
the first group, with downward ticks indicating each group
from which it differed. Asterisks above downward ticks
indicate significance level. Fiber size distributions were
compared by two-way ANOVA at each bin size (Prism 5,
GraphPad). A significant interaction (Drug*Genotype p <
0.05) is marked by an asterisk and a significant genotype
(p < 0.05) effect is marked by a dagger sign. Correlations
were determined by Pearson (Gaussian) or Spearman
(non-parametric) tests.
Results
The Akt/mTOR signaling axis is altered in
dystroglycanopathy muscle
Abnormal intracellular signaling has been reported in
various forms of muscular dystrophy, including other
DGC-related diseases (reviewed in [44]), but not in
dystroglycanopathy. To determine whether Akt/mTOR
signaling is altered in dystroglycanopathy mice, we
examined the activation status of pathway proteins in
fasted Myf5/Fktn KO muscle from mice aged 17–
25 weeks, an age range with substantive remodeling of
the muscle compartment. Myf5/Fktn KO mice were
selected for this study because (1) Fktn-deficiency is the
most common form of congenital dystroglycanopathy;
(2) this conditional knockout model bypasses embryonic
lethality associated with total Fktn loss; and (3) Fktn
excision is initiated during muscle development causing
moderate to severe dystroglycanopathy, similar to the
phenotypic spectrum observed in human patients. As
expected, Myf5/Fktn KO mice had significantly less
functional αDG glycosylation in solubilized hind limb
skeletal muscle than age-matched LC mice (Fig. 1a). Akt
activation status was not different in Myf5/Fktn KO
compared to LC mice using either T308 or S473 nor-
malized to total Akt protein (Fig. 1a, b). In contrast, the
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activated pool of mTOR, the kinase subunit of mTORC1
and mTORC2, was increased (phospho-S2448/total
mTOR) (Fig. 1a, b). mTOR serine 2448 is phosphory-
lated in a feedback loop by mTORC1 substrate S6 kinase
1 [45, 46], indicating elevated mTORC1 activity in the
skeletal muscle of Myf5/Fktn KO compared to LC.
Despite this indication of elevated S6 kinase activity,
phosphorylation of its downstream target, translation
initiator ribosomal protein S6, was not significantly
increased in Myf5/Fktn KO vs. LC mice relative to the
total S6 protein although total S6 protein was elevated
(Fig. 1a, b; Additional file 1). The considerable variability
in expression of Akt and S6 proteins in Myf5/Fktn KO
mice (Additional file 1) may reflect differences in the
severity of muscular dystrophy within the aged knockout
cohort. Therefore, the iliopsoas muscle was examined
histologically for inter-individual disease pathology. The
iliopsoas was chosen because it is a proximal muscle
more severely affected in Myf5/Fktn KO mice and has a
relatively small cross-sectional area with less intra-
section variability in pathology. As expected, there was
an extensive fibrosis (increased collagen VI, ColVI) and
variation in muscle fiber size in iliopsoas muscles of the
aged Myf5/Fktn KO mice, but dystrophy in some mice
was more severe than in others (Fig. 1c, d). When total
S6 protein expression was plotted versus ColVI fibrosis
for individual Myf5/Fktn KO study mice, there was a sig-
nificant positive correlation (Pearson r = 0.8147; Fig. 1d).
Therefore, some variation in cellular signaling pathways
may be explained by a loss of muscle fibers and/or an
increase in the fibrotic content of the muscle compart-
ment in late-stage dystrophic Myf5/Fktn KO animals.
To determine whether abnormal activation of mTOR in
KO muscle is due to a change in its ability to integrate
input from external ligands, we probed the pathway by
acute activation with insulin in Myf5/Fktn KO and LC
Fig. 1 mTOR is activated in aged, fasted Myf5/Fktn KO muscle. a Western blot analysis of solubilized protein from the hind limb muscle of Myf5/Fktn LC
and KO mice. b Quantification of Akt phosphorylation at T308 and S473, mTOR phosphorylation at S2448, S6 phosphorylation at S235/236, relative to total
Akt, mTOR, and S6 protein, respectively, as a measure of protein activation. mTOR phosphorylation at S2448 normalized to total mTOR is significantly
increased in KO muscle. Two-tailed Student’s t test; *p< 0.05. c Representative images of iliopsoas muscle from aged LC or KO mice. H&E staining and
dystrophin (red), ColVI (green), and DAPI (blue) immunofluorescence are shown. Scale bar 100 μm. (d, Left) Quantification of ColVI in iliopsoas of aged mice
reveals significantly increased collagen content in KO muscle. Two-tailed Student’s t test; *p< 0.05. (d, Right) Total S6 protein correlates with ColVI quantity
in KO muscle (Pearson r= 0.8147; p= 0.0256). n= 8 Myf5/Fktn LC and 8 Myf5/Fktn KO mice (n= 7 per group for ColVI analysis due to tissue artifacts)
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mice. Twelve-week-old mice were chosen because
muscle fibers populate a relatively larger proportion of
the tissue compartment in Myf5/Fktn KO muscle at
this time point. Animals were fasted for a total of 12 h
and treated with an insulin challenge or vehicle in the
last 30 min. The dystroglycan glycosylation deficiency
was confirmed in KO mice and S6 ribosomal protein
activation was tested by Western blot as a downstream
readout of mTORC1 activity. Insulin significantly in-
duced activation of S6, the target of mTORC1 substrate
S6 kinase. Phosphorylation at S235/236 relative to S6
protein was increased in both LC (3.84 ± 1.26-fold) and
KO muscle (3.07 ± 0.75-fold) (two-way ANOVA, drug
effect p = 0.0255). To assess basal levels of mTORC1
activity at this age, a separate cohort of mice was dosed
with mTOR inhibitor rapamycin (RAPA) or vehicle 6 h
before muscle collection. RAPA reduced the ratio of S6
phosphorylation to S6 protein in fasted littermates
(4.71 ± 2.40-fold) and Myf5/Fktn KO (7.24 ± 3.55-fold)
compared to time-matched vehicle controls (two-way
ANOVA drug effect p = 0.0147). These results demon-
strate that mTORC1 retains the capacity to respond
to acute activation or inhibition in Myf5/Fktn KO
mice.
mTOR activation is not coincident with loss of functional
αDG glycosylation
Although our results indicate misregulation of mTOR
signaling in Myf5/Fktn KO mice, it is unclear whether
this finding results directly from improper glycosylation
of αDG or from the progressive dystrophic process. For
example, changes in mTOR signaling could arise from
any of these possibilities: first, loss of αDG binding to
laminin could change the activation status of signaling
molecules to directly affect the pathway changes iden-
tified here (e.g., [23]). Second, mTOR signaling could
be initiated by disease processes contributing to the
pathological progression, including muscle regener-
ation [24, 25, 47], differentiation and growth of
replacement fibers [29, 48–50], or fibrosis [51, 52].
Finally, mTOR pathway activation could be a compen-
satory adaptation by the muscle to mitigate damage
burden on the tissue.
To address the first possibility, we employed the whole-
body inducible Fktn-KO (iKO) mouse to induce Fktn exon
2 deletion and subsequent deficiency in αDG glycosylation
post-development, a model we reported previously to have
a reduction of αDG glycosylation as early as 2.5 weeks and
evidence of muscle damage by 8 to 10 weeks post-
tamoxifen [18]. Adult mice were dosed with tamoxifen
and euthanized (fasted) 5 weeks later to ensure that αDG
glycosylation was disrupted, but dystrophic pathology was
not yet present. Iliopsoas of tamoxifen-treated iKO mice
(Tam iKO) were histologically normal but showed reduced
immunoreactivity to IIH6 antibody against the glycosyl-
ated epitope of αDG (Fig. 2a); furthermore, decreased
αDG glycosylation and a shift to lower molecular weight
αDG protein was confirmed by Western blot (Fig. 2b).
Analysis of Akt, mTOR, and S6 activation revealed no
significant differences between Tam LC and Tam iKO
mice (Fig. 2b, c) suggesting that abnormal mTOR signal-
ing is not a direct consequence of αDG hypoglycosylation.
Four-week daily mTORC1 inhibition improves disease
features in dystroglycanopathy mice
These data indicate that mTOR activation in aged Myf5/
Fktn KO is likely related to the dystrophic phenotype
but do not distinguish between potential pathogenic or
protective roles for this signal. Although previous studies
have demonstrated the ability of rapamycin to reduce
the dystrophic phenotype in some models of muscular
dystrophy, complete ablation of mTORC1 signaling
through knockout of raptor, an obligate member of
mTORC1, leads to a dystrophic phenotype in mice [30,
33, 53]. This might indicate that mTORC1 signaling is
necessary for the maintenance of normal skeletal muscle
but becomes pathogenic under disease conditions. To
test whether mTORC1 signaling contributes to path-
ology in Myf5/Fktn KO mice, 8-week-old KO and LC
mice were dosed with 2 mg/kg RAPA or vehicle control
(VEH) daily for 4 weeks by oral gavage. Although RAPA
is approved for clinical use, adverse effects including
nephrotoxicity and hepatotoxicity, have been reported
[54]. To determine whether the 4-week daily RAPA
treatment induced damage to the kidneys or liver, we
evaluated blood urea nitrogen (BUN) and serum alanine
transaminase (ALT) levels in study mice during the
final week of dosing. No effect of RAPA treatment was
observed for either analyte: BUN (mg/dL) = 22.39 ±
2.979, VEH LC; 20.37 ± 2.698, RAPA LC; 17.50 ± 3.70,
VEH KO; 22.10 ± 2.88, RAPA KO (two-way ANOVA,
drug p = 0.6812) and ALT (U/L) = 75.73 ± 38.51, VEH
LC; 66.30 ± 21.52, RAPA LC; 86.84 ± 36.78, VEH KO;
and 40.94 ± 13.83, RAPA KO (two-way ANOVA, drug
p = 0.3552). Therefore, we have no evidence of
treatment-related toxicity in the 4-week 2 mg/kg RAPA
dosing regimen to dystroglycanopathy mice.
We employed two separate study designs to enable the
analysis of distinct functional outcomes: in the first
study, we obtained in vivo torque measurements from
ankle dorsiflexors prior to and at the completion of the
dosing regimen and isolated single, fasted muscles for
biochemical analysis. In the second study, tail vein blood
was collected for the determination of serum CK from
study mice before and after a downhill treadmill run to
exhaustion. Isometric torque measurements were taken
across a spectrum of stimulation frequencies (5, 10, 20,
40, 80, 100, 150, and 200 Hz) in order to evaluate
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contractile ability while still simulating physiologic con-
traction, which occurs in rodents between 60 and
100 Hz [55]. Data are plotted as a force-frequency curve
to provide direct measurement of the frequency-
dependence of tetanic contraction and the maximal
torque, which is an indirect measure of maximal muscle
force. Assessment of resultant force-frequency curves
demonstrated an age-related improvement in dorsiflexor
torque (pre vs. post) of VEH LC mice that was absent in
VEH KO mice, indicating that Myf5/Fktn KO mice do
not experience muscle strength improvements typical
with maturation to adulthood (Fig. 3a). In contrast, there
was a significant interaction between frequency and time
(pre vs. post) for both RAPA-treated LC and KO mice
demonstrating robust gains in isometric torque at sev-
eral stimulation frequencies (i.e., 150–200 Hz in RAPA
LC and 80–200 Hz in RAPA KO) (Fig. 3a). Maximal
torque of LC and KO mice receiving RAPA improved by
14.02 ± 4.68 and 14.32 ± 3.66 N*mm/kg body mass,
respectively, compared to a modest increase in VEH LC
(7.92 ± 3.61) and highly variable changes in VEH KO
mice (6.97 ± 12.10 SEM). In the second cohort, 4-week
RAPA treatment significantly increased treadmill run
distances of Myf5/Fktn KO mice normalized to age- and
trial-matched LC mice, corroborating the functional im-
provement seen via muscle force testing (Fig. 3b).
CK values, indicating the presence of muscle damage,
were also notably different between RAPA and VEH KO
mice. First, basal serum CK (pre-treadmill) in VEH KO
mice was not statistically different from LC mice
(Fig. 3c), a finding consistent with our previous work
demonstrating elevated serum CK levels only in young
Myf5/Fktn KO mice [18]. This can be explained by the
gradual replacement of CK-containing muscle fibers
with fibrotic tissue during disease progression, meaning
that fewer muscle fibers are available to leak CK to the
serum in older mice. However, basal serum CK was
increased in RAPA KO mice (Fig. 3c), suggesting a
RAPA-induced delay in Myf5/Fktn KO pathology.
Importantly, serum CK was significantly increased over
basal levels by a downhill exhaustion run in VEH, but
not RAPA, KO mice, suggesting that the 4-week daily
RAPA treatment was protective against muscle injury in
Myf5/Fktn KO mice (Fig. 3c).
If muscle injury were indeed reduced in RAPA KO mice,
regenerative markers might likewise be decreased since
regeneration in dystrophic muscle indicates prior degener-
ation. To evaluate cumulative regeneration across the
Fig. 2 Akt/mTOR signaling is unchanged following loss of αDG glycosylation. a Representative images of littermate (Tam LC) or inducible
knockout (Tam iKO) iliopsoas. H&E and αDG glyco images are shown. Scale bar = 100 μm. b Western blot analysis of solubilized skeletal muscle
from hind limbs of Tam LC or Tam iKO mice. c Quantification of Akt phosphorylation at T308 and S473, mTOR phosphorylation at S2448, and S6
phosphorylation at S235/236 relative to total Akt, mTOR, and S6 protein, respectively, as a measure of protein activation. Data are presented as
mean ± SEM. n = 9 per group
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timeline of the dosing study, we analyzed central nucle-
ation (CN), which persists for several weeks to months
following a regeneration event, in muscle fibers of the
iliopsoas [56]. RAPA KO mice had significantly fewer
centrally nucleated fibers compared to VEH KO mice
(Fig. 4a, b). However, this could signify either that
RAPA treatment reduces muscle damage or that it
inhibits subsequent regeneration. To clarify this point,
we assessed levels of embryonic myosin heavy chain
(eMHC)-positive fibers, which transiently mark regener-
ation, in iliopsoas of RAPA-study mice. eMHC-positive
fibers were unchanged between VEH and RAPA KO
iliopsoas and were increased compared to drug-matched
LC iliopsoas (two-way ANOVA, drug p = 0.9917, genotype
p = 0.0002) (Fig. 4a, b). Together, these results indicate
that muscles in RAPA KO mice retain regenerative cap-
acity in the short term and support a myoprotective effect
of RAPA treatment.
Fktn-deficient dystrophic muscle exhibits notable fiber
size variability populated by an abundance of both small,
atrophic fibers and larger, hypertrophic fibers. Since
mTOR is a well-studied regulator of muscle fiber size,
Fig. 3 Four-week daily RAPA treatment improves functional outcomes in Myf5/Fktn KO mice. a Force-frequency curves showing in vivo
force measurements taken from tibialis anterior muscles of daily RAPA study mice prior to and at completion of RAPA or VEH dosing.
Two-way repeated measures ANOVA with Bonferroni’s post-test. *p < 0.05; **p < 0.01; ***p < 0.001. n = 5 mice per group. b Comparison of downhill
treadmill distances run by VEH and RAPA KO mice. Data are presented as the proportion of KO distance normalized to respective age- and treatment-
matched LC mice from the same treadmill run. Two-tailed Student’s t test. *p < 0.05. n = 7 mice per group. c Serum creatine kinase analysis of tail vein
bleeds taken from daily RAPA study mice at the end of dosing (left, pre-tread) or 2 h after a downhill run to exhaustion (right, post-tread). Two-way
ANOVA with Bonferroni’s post-test of all pairs. *p < 0.05; **p < 0.01; ***p < 0.001. n = 6, VEH and RAPA LC; n = 7, VEH and RAPA KO
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we hypothesized that RAPA treatment might alter this
distribution in treated mice. Cross-sectional minimum
fiber diameters were measured for all muscle fibers in
the iliopsoas of RAPA-study mice. Littermate mice show
more evenly distributed minimum fiber diameters, with
few or no atrophic fibers. In contrast, fibers from both
RAPA and VEH KO muscle had significantly higher
proportions of small-sized fibers and an expanded
proportion of fibers with minimum diameters greater
than 25 μm (Fig. 4c). In accordance with this, we
observed a significant effect of genotype on fiber size at
6 of the 12 bin sizes. Furthermore, there was a signifi-
cant Drug*Genotype interaction at the 5–7.5, 7.5–10,
15–17.5, 17.5–20, 20–22.5, and 22.5–25 μm minimum
fiber diameter bins. To confirm that differences in fiber
size between VEH and RAPA KO mice were not due
Fig. 4 Daily RAPA reduces central nucleation and alters fiber size of Myf5/Fktn KO iliopsoas. a Images from iliopsoas muscles of VEH- or RAPA-treated LC
and KO mice. H&E, functionally glycosylated αDG, and core αDG/embryonic myosin heavy chain (eMHC) are shown. Nuclear DAPI counterstain is shown in
blue. Scale bar = 100 μm. Asterisks denote identical tissue locations across images. Muscle fiber regeneration as measured historically by (b, left) central
nucleation (CN) or acutely by (b, right) eMHC. Data are plotted as ((#positive fibers/total fibers)*100). Two-way ANOVA; *p< 0.05; ***p< 0.001. n= 10 VEH
LC, n= 9 RAPA LC, n= 12 VEH KO, n= 12 RAPA KO. c Distribution of muscle fiber minimum diameter from iliopsoas of VEH- and RAPA-treated LC and KO
mice. Fibers are grouped into bins of 2.5 μm. Two-way ANOVA performed for each bin. *, Drug*Genotype p< 0.05; †, Genotype p< 0.05. n= 5 VEH LC
(tissue artifact), n= 5 RAPA LC (tissue artifact), n= 7 VEH KO, n= 7 RAPA KO
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simply to a reduction in small, regenerating fibers, we
further analyzed distributions of regenerated (in KOs
only) and non-regenerated muscle fibers separately. We
found little difference between the fiber diameter distri-
butions of all fibers compared to non-regenerated fibers
only; furthermore, the proportions of regenerated fibers
at each bin size were different only at the 20–22.5-μm
bin, indicating that changes in the overall fiber size
distributions are likely not attributable to differences in
the pool of regenerating fibers (Additional file 2). Thus,
RAPA shifted fiber size towards larger values in KO
muscle but relatively smaller values in LC muscle, fur-
ther supporting the idea that Fktn-deficient muscle has
some abnormal, RAPA-sensitive signaling activity.
Muscle damage is often followed by an inflammatory
response involving macrophage infiltration that helps to
mediate tissue repair. However, dystrophic muscle experi-
ences repeated cycles of damage and repair with persist-
ence of the inflammatory phenotype [57, 58]. As RAPA
treatment appears to offer protection against muscle dam-
age, we hypothesized that localized tissue inflammation
might be reduced in RAPA-treated Myf5/Fktn KO mice.
We incubated iliopsoas muscle sections from study mice
with an antibody detecting CD11b, a common marker for
mature macrophages that may also be expressed by granu-
locytes, dendritic cells, and NK cells [59]. Tissues from
both LC and KO mice were positive for isolated, “resident”
immune cells; however, KO iliopsoas also displayed
regions of intense staining likely marking major inflamma-
tory invasion (Fig. 5a). Importantly, RAPA KO mice had
significantly less CD11b-positive fluorescence than VEH
KO mice, indicating reduced inflammation with RAPA
treatment (Fig. 5b). To determine if changes in tissue
immune cell content corresponded to altered levels of cyto-
kines in RAPA KO mice, we tested solubilized protein from
the quadriceps muscle of study mice for the presence of
pro-inflammatory (interleukin-1β, monocyte chemotactic
protein-1, tumor necrosis factor α) cytokines in multiplex
via MILLIPLEX Map assay. We observed a significant effect
of genotype on IL-1β levels when normalized to assay back-
ground; however, we noted no differences in other pro-
inflammatory cytokines tested (Additional file 3A). Thus,
IL-1β appears to be a RAPA-insensitive modulator of
inflammation in dystroglycanopathy muscle.
Although the muscle possesses considerable potential
for regeneration, dystrophic muscle eventually loses
regenerative capacity, due at least in part to chronic
inflammatory conditions [58]. Failed muscle regener-
ation frequently results in the replacement of functional
muscle with fibrotic scar tissue, comprised largely of
excess extracellular matrix proteins. Consistent with a
fibrotic phenotype in Fktn-deficient muscle, transform-
ing growth factor-β (TGF-β), a major fibrogenic cyto-
kine, was significantly increased in muscle of KO relative
to LC study mice as determined by MILLIPLEX Map
analysis, but we did not detect any RAPA-mediated re-
duction in TGF-β (Additional file 3B). However, extra-
cellular matrix protein ColVI, which accumulates
abnormally in dystrophic muscle [60, 61], was increased
in histological sections of iliopsoas muscle of VEH KO
mice, demonstrating substantial fibrosis in 12-week-old
dystrophic muscle, but was significantly reduced in
RAPA KO mice (Fig. 6a, b). In fact, ColVI staining was
not significantly different between the RAPA LC and
RAPA KO groups in the iliopsoas. Fibrosis is a key factor
underlying mortality in muscular dystrophies because
Fig. 5 Four-week daily RAPA treatment decreases immune cell infiltration in iliopsoas. a Images from transverse sections stained for macrophage
marker CD11b (green), with dystrophin (red) and nuclear DAPI (blue) counterstains. Scale bar = 100 μm. b Quantification of CD11b-positive areas in
iliopsoas of daily study mice. Data are presented as the proportion green pixels per tissue/total pixels per tissue. Two-way ANOVA with Bonferro-
ni’s post-test; *p < 0.05; **p < 0.01. n = 10 VEH LC, n = 11 RAPA LC, n = 12 VEH KO, n = 12 RAPA KO
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fibrotic accumulation in the diaphragm reduces its con-
tractile ability and ultimately leads to respiratory failure.
Importantly, we also observed a significant decrease in
the fibrotic area of RAPA KO compared to VEH KO
diaphragms (Fig. 6a, b), demonstrating the therapeutic
potential of RAPA treatment for dystroglycanopathies.
mTORC1 signaling correlates with levels of pathological
markers in dystroglycanopathy muscle
As mentioned previously, mTOR signaling has been linked
to a number of muscle maintenance and disease processes,
including regeneration and fibrosis. While the 4-week
RAPA treatment improved histopathological features in
treated Myf5/Fktn KO mice, its specific site of action is
unclear. In particular, mTORC1 could be hyper-activated in
only a subset of cells within the muscle compartment. Fur-
thermore, because of ongoing regeneration and muscle
remodeling in dystrophic tissue, the normal equilibrium of
various resident cell types within the muscle niche likely
changes as the disease state progresses. In order to evaluate
whether a subset of cells and/or cell types demonstrate
increased mTORC1 activity, we stained iliopsoas muscles
from daily RAPA study mice with an antibody-detecting
phosphorylation of S6 ribosomal protein, which is
dependent on the mTOR substrate S6-kinase for activation.
While levels of pS6 were below detection in LC mice, sec-
tions from KO mice revealed regions of robust staining
(Fig. 7a). pS6 was observed in both the muscle fibers and
endomysial spaces of KO iliopsoas, demonstrating that
mTORC1 activation is not limited to a single cell type.
Activated S6 was also observed in RAPA KO iliopsoas, as
expected, because muscles analyzed were approximately
18 h to 2.5 days since the last VEH or RAPA dose for the
muscle torque and treadmill RAPA studies, respectively. To
delineate the potential locations of mTOR-mediated patho-
logical processes, we correlated pS6 areas to markers of
fibrosis (ColVI) or acute regeneration (eMHC). In VEH KO
muscle, pS6 correlated weakly with eMHC levels (Pearson
r = 0.6169) but tracked closely with levels of ColVI (Pearson
r = 0.8236). In contrast, pS6 correlated more closely to
Fig. 6 Fibrosis is reduced in iliopsoas and diaphragm of RAPA-treated Myf5/Fktn KO mice. a Representative images from iliopsoas (top) or diaphragm
(bottom) of daily study mice stained with dystrophin/ColVI; nuclear DAPI counterstain shown in blue. Scale bar = 100 μm b Quantification of muscle
fibrosis, ColVI-positive area, in iliopsoas (left) or diaphragm (right) muscles, detected by immunofluorescence and counted as positive (green) pixels per
tissue/total pixels per tissue. Two-way ANOVA; *p < 0.05; ***p < 0.001. Ilio: n = 9 VEH LC, n = 8 RAPA LC, n = 12 VEH KO, n = 12 RAPA KO. Dia: n = 5 VEH
LC, n = 6 RAPA LC, n = 7 VEH KO, n = 7 RAPA KO
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eMHC (Spearman r = 0.7676) than to ColVI (Pearson r=
0.7066) in RAPA-treated KO muscle (Fig. 7b). Altogether,
these results indicate a role for mTORC1 in both the regen-
erative and fibrotic processes of dystrophic muscle and sug-
gest that RAPA may act to inhibit these signaling events in
fibroblasts.
Daily RAPA treatment partially reduces elevated
autophagic flux in Fktn-deficient muscle
Recent work in mouse models has identified defective
macroautophagy as a therapeutic target in dystrophic
muscle [62, 63]; furthermore, pharmacologic or genetic
reversal of this phenomenon, including by RAPA,
appears to improve disease phenotype [33, 64, 65]. To
probe levels of autophagy in Fktn-deficient muscle, we
analyzed expression of the autophagosome-associated
proteins Beclin-1 and LC3B by Western blot. We found
a significant effect of genotype on relative quantities of
the lipidated, autophagosome-partitioned form of LC3B
(LC3B-II, lower band) (Fig. 8a, b). In addition, there was
an interaction of drug and genotype on Beclin-1 levels
with RAPA promoting an increase in littermate, but a
decrease in KO mice; Beclin-1 was significantly elevated
in VEH KO compared to VEH LC mice, in the post-test
analysis (Fig. 8a, b). Western blot analysis of the autoph-
agy regulator Vps15 also demonstrated a genotype effect,
but the increased level of this protein in KO muscle was
unaffected by RAPA treatment (data not shown). These
data provide evidence of increased autophagy in dystro-
glycanopathy muscle, in contrast to reports in other
models of muscular dystrophy. However, because
autophagy functions to target defective proteins and or-
ganelles for cellular removal [66, 67], increased levels of
Beclin-1 and LC3B-II in Fktn-deficient muscle likely
point to clearance of tissue components following dam-
age. For example, genes involved in mitochondrial
biogenesis are upregulated following muscle injury as
damaged organelles are replaced in the tissue [68].
Furthermore, in mdx muscle, pharmacologic modulation
of 5′ adenosine monophosphate-activated protein kinase
Fig. 7 pS6 localizes to myofiber- and non-myofiber-specific niches in iliopsoas of Myf5/Fktn KO mice. a Images stained against phosphorylated S6
(S235/236) ribosomal protein (red) with basement membrane perlecan (green) and nuclear DAPI (blue) counterstains shown. Scale bar = 100 μm. b
Plots comparing pS6-positive areas to percentages of regenerating fibers (eMHC, top) or to fibrotic areas (ColVI, bottom) in iliopsoas of VEH (left)
and RAPA (right) KO mice. Pearson r value shown for all groups except RAPA KO eMHC (Spearman r shown, D’Agostino and Pearson omnibus
normality test failed)
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(AMPK) enhanced autophagy with an associated improve-
ment of mitochondrial function and a coincident reduction
of disease burden [64]. These data suggest a link between
autophagy and mitochondrial remodeling in muscle. To de-
termine whether RAPA treatment affects mitochondrial
function, we assayed the activity of succinate dehydrogen-
ase (SDH), a mitochondrial enzyme involved in oxidative
phosphorylation at steps in both the citric acid cycle and
the electron transport chain. We observed lower SDH
activity in KO compared to LC muscle when normalized to
total tissue mass but found no difference between RAPA
and VEH KO mice. RAPA LC muscle tended to have more
SDH activity than VEH LC muscle, but these differences
were not statistically significant in the cohort tested (n = 4
RAPA LC, n = 3 VEH LC) (Additional file 4). Thus, RAPA-
mediated improvements to Myf5/Fktn KO muscle appear
to occur independently of mitochondrial function and
further highlight the divergence of fukutin- and dystrophin-
deficient muscle with respect to autophagic phenotype.
Altogether, our results point to a myoprotective effect of
RAPA treatment that may delay the progression of disease
in dystroglycanopathy tissue.
Discussion
Several muscular dystrophies arise from the loss of the
structural linkage between the extracellular matrix and
the intracellular cytoskeleton (reviewed in [69, 70]).
While increased susceptibility of the sarcolemma to
damage is a well-studied component of disease etiology,
some signaling functions have also been ascribed to the
DGC. Growth-receptor bound protein 2 (Grb2) has been
shown to bind intracellularly to βDG, providing a pos-
sible link between the DGC and mTOR signaling
through the extracellular signal-regulated kinase/riboso-
mal S6 kinase (ERK/RSK) pathway [71, 72]. Indeed, dis-
ruption of DG-laminin binding reduces ERK [73] and
Akt activation and increases apoptosis in cultured myo-
tubes [23]. However, consistent with the data presented
here, a direct connection between αDG glycosylation
and mTOR activation has not been demonstrated. Still,
accumulating evidence suggests a critical role for mTOR
signaling in the development and maintenance of the
skeletal muscle [24, 53, 74–76].
Abnormal age- and muscle-dependent mTOR activa-
tion has been observed previously in the skeletal muscle
of the mdx mouse, a mild model of dystrophin-deficient
muscular dystrophy [30, 62, 77]. Furthermore, simultan-
eous increases in mTOR phosphorylation and protein
content have also been described in mdx diaphragm at
10 weeks [64]. Here, we provide evidence of increased
mTORC1 activation in aged Fktn-deficient muscle, a
model of moderate to severe muscular dystrophy; how-
ever, changes in mTOR signaling were not intrinsic to
the dystroglycan glycosylation defect as they did not
Fig. 8 Autophagy proteins are upregulated in dystroglycanopathy
muscle. aWestern blot analysis showing levels of autophagy proteins
Beclin-1 and LC3B. GAPDH was used as a loading control. b Densitometric
analysis of Beclin-1 (top) and LC3B-II (lower band, bottom) protein levels,
normalized to GAPDH loading control. Two-way ANOVA; ***p< 0.001
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arise until after the development of muscle pathology.
Thus, activation of mTOR likely reflects the fibrotic pro-
gression that occurs during the dystrophic process. mTOR
is indeed a known regulator of extracellular matrix protein
synthesis in cultured fibroblasts, a process with apparent
sensitivity to RAPA [78, 79], and is activated in primary
muscle fibroblasts in response to growth stimuli [52]. It is
therefore possible that the therapeutic benefit of RAPA
treatment in dystroglycanopathy mice proceeds by imped-
ing the development of endomysial fibrosis.
In agreement with our findings, mTORC1 inhibition
has also shown therapeutic benefit in mdx mouse,
although a consistent mechanism of action has not yet
been established (e.g., [30, 33]). The outcomes reported
in Fig. 3 seem to support a RAPA-mediated delay of
disease progression in dystroglycanopathy muscle. Func-
tional phenotypes of LC and KO mice are expected to
diverge with the advancement of muscle disease, as was
the case for in vivo torque measurements: VEH LC, but
not VEH KO mice, demonstrated age-associated
increases in torque following the 4-week dosing study;
however, both RAPA LC and KO animals demonstrated
an increase in torque at the conclusion of dosing. Ana-
lysis of downhill treadmill run distances between KO
treatment groups shows a similar finding as four of
seven RAPA-treated ran KO mice ran at least half the
distance of their respective age- and treatment-matched
controls, compared to a single instance in the VEH KO
group. It is unclear why little to no improvement was
observed in the remaining three RAPA KO mice,
although dystrophic phenotypes of Myf5/Fktn KO mice
have been reported to be variable [18]. If RAPA treat-
ment is capable of delaying disease progression, but
incapable of reversing dystrophy, then mice with more
severe muscle involvement at the commencement of the
dosing schedule might have a correspondingly weaker
response to the drug.
Recent mechanistic studies have focused on the role
of autophagy in both normal and dystrophic muscle,
with the finding that consistent Akt or mTORC1 acti-
vation inhibits autophagic processes in a way that is
damaging to muscle tissue [80]. Indeed, increasing evi-
dence demonstrates that restoration or augmentation
of autophagy can improve pathological features of
muscle disease [33, 63, 64, 81]. Autophagy serves a key
function in the clearance of damaged organelles from
the cytosolic space, and accumulation of these dysfunc-
tional cellular structures likely underpins the associ-
ation between impaired autophagy and the dystrophic
phenotype [63, 82]. Conversely, unchecked activation of
the autophagy pathway is also detrimental to the
muscle and leads to atrophy or myopathy [83, 84].
Here, we report that proteins involved in autophago-
some formation are upregulated in dystroglycanopathy
muscle, suggesting that autophagy is not deficient in dys-
troglycanopathy muscle (Fig. 8). However, we cannot
distinguish between pathogenic deregulation of protein/
organelle degradation pathways or an increase in cellular
component recycling following repeated bouts of myone-
crosis. In either case, RAPA appears to partially relieve the
altered autophagic phenotype of Myf5/Fktn KO mice.
Rapamycin (sirolimus) and related rapalogs (everolimus,
temsirolimus) are FDA-approved drugs for the treatment
of tuberous sclerosis complex (TSC), lymphangioleiomyo-
matosis (sirolimus), renal transplant (sirolimus, everoli-
mus), breast cancer, pancreatic cancer, subependymal
giant astrocytoma (SEGA, everolimus), and renal cell
carcinoma (everolimus, temsirolimus) [54]. Importantly,
sirolimus and everolimus are in use as single and combin-
ation drug therapies in pediatric populations for TSC,
TSC-related SEGA, and for children 13 years and up with
renal transplant [85–89]. The 2-mg/kg RAPA dose used
here, relatively low for mouse experiments, by allometric
scaling is approximately equivalent to 5.7 mg/m2 [90]. In
comparison, TSC and SEGA trials used doses as low as
1.5 or 3 mg/m2 (sirolimus and everolimus, respectively)
and as high as ~4 or 4.5 mg/m2 (sirolimus, everolimus,
respectively). In clinical trials evaluating sirolimus for
renal transplant, a loading dose of 15 mg with a 5-mg
maintenance dose (corresponding to 7.89 and 2.63 mg/
m2, respectively, based on 1.9 m2 average male body area)
was found to be safe. Thus, while the dose described in
our study is at the higher range of dosage in pediatric
patients, there is no evidence to support that this dose is
too high to be considered clinically relevant. Potential
adverse events, such as immunosuppression, metabolic
changes, and hypertension, need to be considered; how-
ever, the clinical cohorts with adverse event reporting
are predominately cancer or transplant patients, who
consequently have significant comorbidities and com-
bined therapies that may or may not be relevant to a
dystroglycanopathy patient population [91]. Notably,
seven children, ranging in age from 4 to 16 years old
received rapamycin for intractable epilepsy due to
tuberous sclerosis complex; daily treatment for
12 months was reported without significant side effects
[86]. While an absence of liver and kidney toxicity in
the fourth week of daily treatment in this study cannot
exclude potential adverse events with longer RAPA
treatment schedules in dystroglycanopathy mice or
patients, previous work found that long-term RAPA
treatment (estimated 2.2 mg/kg/day) increased lifespan
of heterogeneous wild-type mice, with half of the study
mice receiving therapy for approximately 75 weeks
[92]. Therefore, while there is evidence that chronic
RAPA treatment may be tolerable in mouse and human
studies, caution is still warranted. Additional studies
will be necessary to confirm the therapeutic value of
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long-term mTORC1 inhibition in dystroglycanopathy and
to determine the optimal timing of treatment to ensure
maximal tissue response.
Conclusions
We found evidence of elevated mTOR activation in
later-stage dystroglycanopathy muscle of Fktn-deficient
mice. Younger mice treated for 4 weeks with RAPA dis-
played a reduction in fibrosis and muscle damage and
had improved muscle function. We propose that RAPA
may protect dystrophic muscle from damage to delay
progression of disease and inhibit fibrotic remodeling.
This suggests that mTORC1 signaling may be a viable
therapeutic target for dystroglycanopathy-type muscu-
lar dystrophies, but further work is needed to define
ideal treatment conditions.
Additional files
Additional file 1: (A) Quantification of Akt or S6 protein expression in
17–25-week-old Myf5/Fktn LC and KO mice. Two-tailed Student’s t test.
*p < 0.05. (B) Akt expression has a significant correlation with the proportion
of ColVI+ area in KO muscle (Pearson r = 0.7922, p = 0.0337). n = 8 Myf5/Fktn
LC and 8 Myf5/Fktn KO mice (n = 7 per group for ColVI analysis due to tissue
artifacts). (PDF 325 kb)
Additional file 2: (A) Distribution of muscle fiber minimum diameter
from non-regenerated muscle fibers in iliopsoas of VEH- and RAPA-treated
LC and KO mice. Fibers are grouped into bins of 2.5 μm. Two-way ANOVA
performed for each bin. *, Drug*Genotype p < 0.05; †, Genotype p < 0.05.
n = 5 VEH LC (tissue artifact), n = 5 RAPA LC (tissue artifact), n = 7 VEH KO,
n = 7 RAPA KO. (B) Distribution of muscle fiber minimum cross-sectional
diameter from regenerated muscle fibers in iliopsoas of VEH- and
RAPA-treated KO mice. Fibers are grouped into bins of 2.5 μm. Regenerated
fiber numbers range from 64 to 360 in VEH KO mice and 5–217 in RAPA KO
mice. n= 7 VEH KO, n= 6 RAPA KO (mouse sample with only five regenerating
fibers was excluded from fiber size bin analysis). Two-tailed Student’s t test; *p
< 0.05. (PDF 276 kb)
Additional file 3: (A) Fold-change over background values for
pro-inflammatory cytokines (IL-1β, MCP-1, and TNF-α) tested via MILLIPLEX
Map assay in quadriceps of daily RAPA study mice. (B) Fold-change over
background values for TGF-β tested via MILLIPLEX Map assay in quadriceps
muscle of daily RAPA study mice. (TIF 694 kb)
Additional file 4: Tissue mass-normalized values of cytochrome C
reduced in vitro by succinate dehydrogenase from homogenized TAs of
VEH- or RAPA-treated LC and KO mice. Two-way ANOVA. (PDF 291 kb)
Abbreviations
ANOVA: analysis of variance; CK: creatine kinase; CN: central nucleation;
ColVI: collagen VI; DGC: dystrophin-glycoprotein complex; DMD: Duchenne
muscular dystrophy; eMHC: embryonic myosin heavy chain; ERK: extracellular
signal-regulated kinase; GAPDH: glyceraldehyde 3-phosphate dehydrogenase;
Grb2: growth-receptor bound protein 2; H&E: hematoxylin and eosin;
iKO: inducible knockout; KO: knockout; LC: littermate control; mTOR: mammalian
target of rapamycin; mTORC1: mTOR complex 1; mTORC2: mTOR complex 2;
Myf5: myogenic factor 5; PBS: phosphate-buffered saline; PDK1: phosphoinositide-
dependent kinase 1; PDK2: phosphoinositide-dependent kinase 2;
RAPA: rapamycin; RSK: ribosomal s6 kinase; SDH: succinate dehydrogenase;
TA: tibialis anterior; Tam: tamoxifen; TGF-β: transforming growth factor-β;
VEH: vehicle; αDG: α-dystroglycan; βDG: β-dystroglycan.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AMB, SJF, and JAC designed the study; SJF, JL, JAC, and AMB performed
experiments; SJF, JL, JAC, AP, KBP, and MJF analyzed data; SJF and AMB wrote
the manuscript. All authors provided comments and revisions to the
manuscript; all authors have approved the final manuscript.
Acknowledgements
Myf5-cre, floxed Fktn, and Tam-cre/floxed Fktn mice and antibodies IIH6 and
7D11 were kind gifts from Dr. Kevin Campbell (U. Iowa). We thank Brionna Hall,
Nafisa Chowdhury, and Peyton Ledford for technical support and Jamie Barber
for assistance with Luminex xMap experimental set-up and instrumentation.
Funding
This work was supported in part by the National Institute of General Medical
Sciences (R01GM111939, to co-investigator AMB), the National Institute of Arthritis
and Musculoskeletal and Diseases (R15AR065077, to AMB), the University of
Georgia Dean’s Pharmacy Special Endowment Fund Seed Grant (AMB), and the
University of Georgia College of Pharmacy (AMB).
Author details
1Department of Pharmaceutical and Biomedical Sciences, University of
Georgia, 240 W. Green St., Athens, GA 30602, USA. 2Department of
Kinesiology, University of Georgia, Athens, GA 30602, USA. 3Regenerative
Bioscience Center, University of Georgia, Athens, GA 30602, USA.
Received: 1 March 2016 Accepted: 4 May 2016
References
1. Ervasti JM, Campbell KP. Membrane organization of the dystrophin-glycoprotein
complex. Cell. 1991;66:1121–31.
2. Han R, Kanagawa M, Yoshida-Moriguchi T, Rader EP, Ng RA, Michele DE,
et al. Basal lamina strengthens cell membrane integrity via the laminin G
domain-binding motif of alpha-dystroglycan. Proc Natl Acad Sci USA. 2009;
106:12573–9.
3. Ervasti JM, Campbell KP. A role for the dystrophin-glycoprotein complex as a
transmembrane linker between laminin and actin. J Cell Biol. 1993;122:809–23.
4. Chiba A, Matsumura K, Yamada H, Inazu T, Shimizu T, Kusunoki S, et al. Structures
of sialylated O-linked oligosaccharides of bovine peripheral nerve alpha-
dystroglycan. The role of a novel O-mannosyl-type oligosaccharide in the
binding of alpha-dystroglycan with laminin. J Biol Chem. 1997;272:2156–62.
5. Hara Y, Kanagawa M, Kunz S, Yoshida-Moriguchi T, Satz JS, Kobayashi YM,
et al. Like-acetylglucosaminyltransferase (LARGE)-dependent modification of
dystroglycan at Thr-317/319 is required for laminin binding and arenavirus
infection. Proc Natl Acad Sci U S A. 2011;108:17426–31.
6. Live D, Wells L, Boons GJ. Dissecting the molecular basis of the role of the
O-mannosylation pathway in disease: alpha-dystroglycan and forms of
muscular dystrophy. Chembiochem. 2013;14:2392–402.
7. Praissman JL, Live DH, Wang S, Ramiah A, Chinoy ZS, Boons GJ, et al.
B4GAT1 is the priming enzyme for the LARGE-dependent functional
glycosylation of alpha-dystroglycan. Elife. 2014. doi:10.7554/eLife.03943.
8. Willer T, Inamori K, Venzke D, Harvey C, Morgensen G, Hara Y, et al. The
glucuronyltransferase B4GAT1 is required for initiation of LARGE-mediated
alpha-dystroglycan functional glycosylation. Elife. 2014. doi:10.7554/eLife.03941.
9. Michele DE, Barresi R, Kanagawa M, Saito F, Cohn RD, Satz JS, et al. Post-
translational disruption of dystroglycan-ligand interactions in congenital
muscular dystrophies. Nature. 2002;418:417–22.
10. Kobayashi K, Nakahori Y, Miyake M, Matsumura K, Kondo-Iida E, Nomura Y,
et al. An ancient retrotransposal insertion causes Fukuyama-type congenital
muscular dystrophy. Nature. 1998;394:388–92.
11. Grewal PK, Holzfeind PJ, Bittner RE, Hewitt JE. Mutant glycosyltransferase
and altered glycosylation of alpha-dystroglycan in the myodystrophy
mouse. Nat Genet. 2001;28:151–4.
12. Longman C, Brockington M, Torelli S, Jimenez-Mallebrera C, Kennedy C, Khalil
N, et al. Mutations in the human LARGE gene cause MDC1D, a novel form of
congenital muscular dystrophy with severe mental retardation and abnormal
glycosylation of alpha-dystroglycan. Hum Mol Genet. 2003;12:2853–61.
13. Endo T. Glycobiology of alpha-dystroglycan and muscular dystrophy. J
Biochem. 2015;157:1–12.
Foltz et al. Skeletal Muscle  (2016) 6:20 Page 16 of 18
14. Kanagawa M, Kobayashi K, Tajiri M, Manya H, Kuga A, Yamaguchi Y, et al.
Identification of a post-translational modification with ribitol-phosphate and
its defect in muscular dystrophy. Cell Rep. 2016;14(9):2209–23.
15. Luz MA, Marques MJ, Santo NH. Impaired regeneration of dystrophin-deficient
muscle fibers is caused by exhaustion of myogenic cells. Braz J Med Biol Res.
2002;35:691–5.
16. Heslop L, Morgan JE, Partridge TA. Evidence for a myogenic stem cell that is
exhausted in dystrophic muscle. J Cell Sci. 2000;113(Pt 12):2299–308.
17. Cote PD, Moukhles H, Lindenbaum M, Carbonetto S. Chimaeric mice
deficient in dystroglycans develop muscular dystrophy and have disrupted
myoneural synapses. Nat Genet. 1999;23:338–42.
18. Beedle AM, Turner AJ, Saito Y, Lueck JD, Foltz SJ, Fortunato MJ, et al. Mouse
fukutin deletion impairs dystroglycan processing and recapitulates muscular
dystrophy. J Clin Invest. 2012;122:3330–42.
19. Foltz SJ, Modi JN, Melick GA, Abousaud MI, Luan J, Fortunato MJ, et al.
Abnormal skeletal muscle regeneration plus mild alterations in mature fiber
type specification in Fktn-deficient dystroglycanopathy muscular dystrophy
mice. PLoS One. 2016;11:e0147049.
20. Goddeeris MM, Wu B, Venzke D, Yoshida-Moriguchi T, Saito F, Matsumura K,
et al. LARGE glycans on dystroglycan function as a tunable matrix scaffold
to prevent dystrophy. Nature. 2013;503:136–40.
21. Kanagawa M, Yu CC, Ito C, Fukada S, Hozoji-Inada M, Chiyo T, et al. Impaired
viability of muscle precursor cells in muscular dystrophy with glycosylation
defects and amelioration of its severe phenotype by limited gene
expression. Hum Mol Genet. 2013;22:3003–15.
22. Ross J, Benn A, Jonuschies J, Boldrin L, Muntoni F, Hewitt JE, et al. Defects in
glycosylation impair satellite stem cell function and niche composition in the
muscles of the dystrophic Large(myd) mouse. Stem Cells. 2012;30:2330–41.
23. Langenbach KJ, Rando TA. Inhibition of dystroglycan binding to laminin
disrupts the PI3K/AKT pathway and survival signaling in muscle cells. Muscle
Nerve. 2002;26:644–53.
24. Kim MH, Kay DI, Rudra RT, Chen BM, Hsu N, Izumiya Y, et al. Myogenic Akt
signaling attenuates muscular degeneration, promotes myofiber
regeneration and improves muscle function in dystrophin-deficient mdx
mice. Hum Mol Genet. 2011;20:1324–38.
25. Marshall JL, Holmberg J, Chou E, Ocampo AC, Oh J, Lee J, et al.
Sarcospan-dependent Akt activation is required for utrophin expression
and muscle regeneration. J Cell Biol. 2012;197:1009–27.
26. Dogra C, Changotra H, Wergedal JE, Kumar A. Regulation of
phosphatidylinositol 3-kinase (PI3K)/Akt and nuclear factor-kappa B signaling
pathways in dystrophin-deficient skeletal muscle in response to mechanical
stretch. J Cell Physiol. 2006;208:575–85.
27. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation
of Akt/PKB by the rictor-mTOR complex. Science. 2005;307:1098–101.
28. Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Bauerlein R, et al. Akt/
mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can
prevent muscle atrophy in vivo. Nat Cell Biol. 2001;3:1014–9.
29. Rommel C, Bodine SC, Clarke BA, Rossman R, Nunez L, Stitt TN, et al.
Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/
mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol. 2001;3:1009–13.
30. Eghtesad S, Jhunjhunwala S, Little SR, Clemens PR. Rapamycin ameliorates
dystrophic phenotype in mdx mouse skeletal muscle. Mol Med. 2011;17:
917–24.
31. Chan YM, Keramaris-Vrantsis E, Lidov HG, Norton JH, Zinchenko N, Gruber
HE, et al. Fukutin-related protein is essential for mouse muscle, brain and
eye development and mutation recapitulates the wide clinical spectrums of
dystroglycanopathies. Hum Mol Genet. 2010;19:3995–4006.
32. Alexander MS, Casar JC, Motohashi N, Vieira NM, Eisenberg I, Marshall JL, et
al. MicroRNA-486-dependent modulation of DOCK3/PTEN/AKT signaling
pathways improves muscular dystrophy-associated symptoms. J Clin Invest.
2014;124:2651–67.
33. Bibee KP, Cheng YJ, Ching JK, Marsh JN, Li AJ, Keeling RM, et al. Rapamycin
nanoparticles target defective autophagy in muscular dystrophy to enhance
both strength and cardiac function. FASEB J. 2014;28:2047–61.
34. Ramos FJ, Chen SC, Garelick MG, Dai DF, Liao CY, Schreiber KH, et al.
Rapamycin reverses elevated mTORC1 signaling in lamin A/C-deficient mice,
rescues cardiac and skeletal muscle function, and extends survival. Sci Transl
Med. 2012;4:144ra03.
35. Pereboev AV, Ahmed N, Thi Man N, Morris GE. Epitopes in the interacting
regions of beta-dystroglycan (PPxY motif) and dystrophin (WW domain).
Biochim Biophys Acta. 2001;1527:54–60.
36. Fortunato MJ, Ball CE, Hollinger K, Patel NB, Modi JN, Rajasekaran V, et al.
Development of rabbit monoclonal antibodies for detection of alpha-
dystroglycan in normal and dystrophic tissue. PLoS One. 2014;9:e97567.
37. Call JA, Warren GL, Verma M, Lowe DA. Acute failure of action potential
conduction in mdx muscle reveals new mechanism of contraction-induced
force loss. J Physiol. 2013;591:3765–76.
38. Call JA, McKeehen JN, Novotny SA, Lowe DA. Progressive resistance
voluntary wheel running in the mdx mouse. Muscle Nerve. 2010;42:871–80.
39. Cooperstein SJ, Lazarow A, Kurfess NJ. A microspectrophotometric method for
the determination of succinic dehydrogenase. J Biol Chem. 1950;186:129–39.
40. Beedle AM, Nienaber PM, Campbell KP. Fukutin-related protein associates
with the sarcolemmal dystrophin-glycoprotein complex. J Biol Chem. 2007;
282:16713–7.
41. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et
al. Fiji: an open-source platform for biological-image analysis. Nat Methods.
2012;9:676–82.
42. Dean RB, Dixon WJ. Simplified statistics for small numbers of observations.
Anal Chem. 1951;23:636–8.
43. Rorabacher DB. Statistical treatment for rejection of deviant values—critical-
values of Dixon Q parameter and related subrange ratios at the 95-percent
confidence level. Anal Chem. 1991;63:139–46.
44. Bhatnagar S, Panguluri SK, Gupta SK, Dahiya S, Lundy RF, Kumar A. Tumor
necrosis factor-alpha regulates distinct molecular pathways and gene
networks in cultured skeletal muscle cells. PLoS One. 2010;5:e13262.
45. Chiang GG, Abraham RT. Phosphorylation of mammalian target of
rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J Biol Chem.
2005;280:25485–90.
46. Holz MK, Blenis J. Identification of S6 kinase 1 as a novel mammalian target of
rapamycin (mTOR)-phosphorylating kinase. J Biol Chem. 2005;280:26089–93.
47. Zhang P, Liang X, Shan T, Jiang Q, Deng C, Zheng R, et al. mTOR is
necessary for proper satellite cell activity and skeletal muscle regeneration.
Biochem Biophys Res Commun. 2015;463:102–8.
48. Ge Y, Wu AL, Warnes C, Liu J, Zhang C, Kawasome H, et al. mTOR regulates
skeletal muscle regeneration in vivo through kinase-dependent and kinase-
independent mechanisms. Am J Physiol Cell Physiol. 2009;297:C1434–44.
49. Goodman CA, Frey JW, Mabrey DM, Jacobs BL, Lincoln HC, You JS, et al. The
role of skeletal muscle mTOR in the regulation of mechanical load-induced
growth. J Physiol. 2011;589:5485–501.
50. Majmundar AJ, Skuli N, Mesquita RC, Kim MN, Yodh AG, Nguyen-McCarty M,
et al. O(2) regulates skeletal muscle progenitor differentiation through
phosphatidylinositol 3-kinase/AKT signaling. Mol Cell Biol. 2012;32:36–49.
51. Gui YS, Wang L, Tian X, Li X, Ma A, Zhou W, et al. mTOR overactivation and
compromised autophagy in the pathogenesis of pulmonary fibrosis. PLoS
One. 2015;10:e0138625.
52. Li ZB, Kollias HD, Wagner KR. Myostatin directly regulates skeletal muscle
fibrosis. J Biol Chem. 2008;283:19371–8.
53. Bentzinger CF, Romanino K, Cloetta D, Lin S, Mascarenhas JB, Oliveri F, et al.
Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic
changes and results in muscle dystrophy. Cell Metab. 2008;8:411–24.
54. FDALabel: Full-text search of drug labeling. http://www.accessdata.fda.gov/
drugsatfda_docs/label/2007/021083s030,021110s038lbl.pdf. Accessed May 6 .
55. Gorassini M, Eken T, Bennett DJ, Kiehn O, Hultborn H. Activity of hindlimb
motor units during locomotion in the conscious rat. J Neurophysiol. 2000;
83:2002–11.
56. McNally EM, Pytel P. Muscle diseases: the muscular dystrophies. Annu Rev
Pathol. 2007;2:87–109.
57. Porter JD, Khanna S, Kaminski HJ, Rao JS, Merriam AP, Richmonds CR, et al. A
chronic inflammatory response dominates the skeletal muscle molecular
signature in dystrophin-deficient mdx mice. Hum Mol Genet. 2002;11:263–72.
58. Mann CJ, Perdiguero E, Kharraz Y, Aguilar S, Pessina P, Serrano AL, et al. Aberrant
repair and fibrosis development in skeletal muscle. Skelet Muscle. 2011;1:21.
59. Leenen PJ, de Bruijn MF, Voerman JS, Campbell PA, van Ewijk W. Markers of
mouse macrophage development detected by monoclonal antibodies. J
Immunol Methods. 1994;174:5–19.
60. Zanotti S, Saredi S, Ruggieri A, Fabbri M, Blasevich F, Romaggi S, et al. Altered
extracellular matrix transcript expression and protein modulation in primary
Duchenne muscular dystrophy myotubes. Matrix Biol. 2007;26:615–24.
61. de Greef JC, Hamlyn R, Jensen BS, O’Campo Landa R, Levy JR, Kobuke K, et
al. Collagen VI deficiency reduces muscle pathology, but does not improve
muscle function, in the gamma-sarcoglycan-null mouse. Hum Mol Genet.
2016;25:1357–69.
Foltz et al. Skeletal Muscle  (2016) 6:20 Page 17 of 18
62. De Palma C, Morisi F, Cheli S, Pambianco S, Cappello V, Vezzoli M, et al.
Autophagy as a new therapeutic target in Duchenne muscular dystrophy.
Cell Death Dis. 2012;3:e418.
63. Grumati P, Coletto L, Sabatelli P, Cescon M, Angelin A, Bertaggia E,
et al. Autophagy is defective in collagen VI muscular dystrophies,
and its reactivation rescues myofiber degeneration. Nat Med.
2010;16:1313–20.
64. Pauly M, Daussin F, Burelle Y, Li T, Godin R, Fauconnier J, et al. AMPK
activation stimulates autophagy and ameliorates muscular dystrophy in the
mdx mouse diaphragm. Am J Pathol. 2012;181:583–92.
65. Hollinger K, Gardan-Salmon D, Santana C, Rice D, Snella E, Selsby JT. Rescue
of dystrophic skeletal muscle by PGC-1alpha involves restored expression of
dystrophin-associated protein complex components and satellite cell
signaling. Am J Physiol Regul Integr Comp Physiol. 2013;305:R13–23.
66. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell. 2008;
132:27–42.
67. Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease
through cellular self-digestion. Nature. 2008;451:1069–75.
68. Wagatsuma A, Kotake N, Yamada S. Muscle regeneration occurs to coincide
with mitochondrial biogenesis. Mol Cell Biochem. 2011;349:139–47.
69. Durbeej M, Campbell KP. Muscular dystrophies involving the dystrophin-
glycoprotein complex: an overview of current mouse models. Curr Opin
Genet Dev. 2002;12:349–61.
70. Sciandra F, Bozzi M, Bianchi M, Pavoni E, Giardina B, Brancaccio A.
Dystroglycan and muscular dystrophies related to the dystrophin-
glycoprotein complex. Ann Ist Super Sanita. 2003;39:173–81.
71. Yang B, Jung D, Motto D, Meyer J, Koretzky G, Campbell KP. SH3 domain-
mediated interaction of dystroglycan and Grb2. J Biol Chem. 1995;270:
11711–4.
72. Spence HJ, Dhillon AS, James M, Winder SJ. Dystroglycan, a scaffold for the
ERK-MAP kinase cascade. EMBO Rep. 2004;5:484–9.
73. Rojek JM, Moraz ML, Pythoud C, Rothenberger S, Van der Goot FG, Campbell
KP, et al. Binding of Lassa virus perturbs extracellular matrix-induced signal
transduction via dystroglycan. Cell Microbiol. 2012;14:1122–34.
74. Schiaffino S, Reggiani C. Fiber types in mammalian skeletal muscles. Physiol
Rev. 2011;91:1447–531.
75. Risson V, Mazelin L, Roceri M, Sanchez H, Moncollin V, Corneloup C, et al.
Muscle inactivation of mTOR causes metabolic and dystrophin defects
leading to severe myopathy. J Cell Biol. 2009;187:859–74.
76. Peng XD, Xu PZ, Chen ML, Hahn-Windgassen A, Skeen J, Jacobs J, et al.
Dwarfism, impaired skin development, skeletal muscle atrophy, delayed
bone development, and impeded adipogenesis in mice lacking Akt1 and
Akt2. Genes Dev. 2003;17:1352–65.
77. Pal R, Palmieri M, Loehr JA, Li S, Abo-Zahrah R, Monroe TO, et al. Src-
dependent impairment of autophagy by oxidative stress in a mouse model
of Duchenne muscular dystrophy. Nat Commun. 2014;5:4425.
78. Shegogue D, Trojanowska M. Mammalian target of rapamycin positively
regulates collagen type I production via a phosphatidylinositol 3-kinase-
independent pathway. J Biol Chem. 2004;279:23166–75.
79. Goc A, Choudhary M, Byzova TV, Somanath PR. TGFbeta- and
bleomycin-induced extracellular matrix synthesis is mediated through
Akt and mammalian target of rapamycin (mTOR). J Cell Physiol. 2011;
226:3004–13.
80. Castets P, Lin S, Rion N, Di Fulvio S, Romanino K, Guridi M, et al. Sustained
activation of mTORC1 in skeletal muscle inhibits constitutive and starvation-
induced autophagy and causes a severe, late-onset myopathy. Cell Metab. 2013;
17:731–44.
81. Whitehead NP, Kim MJ, Bible KL, Adams ME, Froehner SC. A new
therapeutic effect of simvastatin revealed by functional improvement in
muscular dystrophy. Proc Natl Acad Sci U S A. 2015;112:12864–9.
82. Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell.
2011;147:728–41.
83. Malicdan MC, Noguchi S, Nonaka I, Saftig P, Nishino I. Lysosomal
myopathies: an excessive build-up in autophagosomes is too much to
handle. Neuromuscul Disord. 2008;18:521–9.
84. Masiero E, Sandri M. Autophagy inhibition induces atrophy and myopathy
in adult skeletal muscles. Autophagy. 2010;6:307–9.
85. Cardamone M, Flanagan D, Mowat D, Kennedy SE, Chopra M, Lawson JA.
Mammalian target of rapamycin inhibitors for intractable epilepsy and
subependymal giant cell astrocytomas in tuberous sclerosis complex.
J Pediatr. 2014;164:1195–200.
86. Canpolat M, Per H, Gumus H, Yikilmaz A, Unal E, Patiroglu T, et al.
Rapamycin has a beneficial effect on controlling epilepsy in children with
tuberous sclerosis complex: results of 7 children from a cohort of 86. Childs
Nerv Syst. 2014;30:227–40.
87. Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G, et al. Rapamycin
causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol.
2006;59:490–8.
88. Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, et al.
Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.
N Engl J Med. 2010;363:1801–11.
89. Peng ZF, Yang L, Wang TT, Han P, Liu ZH, Wei Q. Efficacy and safety of
sirolimus for renal angiomyolipoma in patients with tuberous sclerosis
complex or sporadic lymphangioleiomyomatosis: a systematic review. J
Urol. 2014;192:1424–30.
90. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human
studies revisited. FASEB J. 2008;22:659–61.
91. Kaplan B, Qazi Y, Wellen JR. Strategies for the management of adverse events
associated with mTOR inhibitors. Transplant Rev (Orlando). 2014;28:126–33.
92. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, et al.
Rapamycin fed late in life extends lifespan in genetically heterogeneous
mice. Nature. 2009;460:392–5.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Foltz et al. Skeletal Muscle  (2016) 6:20 Page 18 of 18
